News stories about Neurometrix (NASDAQ:NURO) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neurometrix earned a news impact score of 0.12 on Accern’s scale. Accern also gave news articles about the medical device company an impact score of 45.6657872410425 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Separately, HC Wainwright reiterated a “buy” rating and issued a $3.00 target price (down from $10.00) on shares of Neurometrix in a report on Friday, October 20th.

Neurometrix (NASDAQ NURO) opened at $1.77 on Tuesday. Neurometrix has a twelve month low of $1.45 and a twelve month high of $7.20. The stock has a market capitalization of $4.15, a price-to-earnings ratio of -0.10 and a beta of 0.33.

TRADEMARK VIOLATION NOTICE: This piece was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://theolympiareport.com/2017/12/26/neurometrix-nuro-earns-media-sentiment-score-of-0-12.html.

Neurometrix Company Profile

NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.

Insider Buying and Selling by Quarter for Neurometrix (NASDAQ:NURO)

Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.